Haematological malignancies, although a broad range of specific disease types, continue to show considerable overlap in classification, and patients are... ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• May 2015

Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• January 2023

Expression of bronchodilator response using forced oscillation technique measurements: absolute versus relative ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2010
• July 2010

Leading international diabetes technology expert Laurel Messer visited Perth to share her experiences with closed loop systems at the Children’s Diabetes Centre’s Community Forum on March 28. ...

• Rio Tinto Children's Diabetes Centre
• News and events

Four Telethon Kids Institute researchers have received prestigious fellowships and four significant cohort studies led or co-led by Telethon Kids have received key grants under two new funding programs supported by the State Government’s Future Health Research and Innovation (FHRI) Fund. ...

• 1. Telethon Kids Institute
• News & Events
• News & Events at Telethon Kids
• 2023
• November

With advancing paediatric healthcare, the use of central venous lines has become a fundamental part of management of neonates and children. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• April 2015

Peter Richmond PC MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials ...

• 1. Telethon Kids Institute
• Projects

Elevated levels of emotional difficulties among school students with T1D and variable levels of support from school staff to assist these students to manage their diabetes at school ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• August 2018

Senior Research Fellow ...

• 1. Telethon Kids Institute
• Contact us
• Our people
• Staff Profiles - H

Itraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking. ...

• 1. Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• January 2021